Let's talk!

Baricitinib in patients with refractory rheumatoid arthritis

  • click to rate

     Baricitinib in patients with refractory rheumatoid arthritis

    Baricitinib is a drug that was approved in 2017 by the U.S. Food and Drug Administration (FDA) to treat adults with moderate-to-severe rheumatoid arthritis (RA) that has not responded to other treatments. The drug is also known as Olumiant, which is a type of Janus kinase inhibitor that works by helping to reduce inflammation in the body.

    Effects suggested from clinical trials

    Baricitinib 2mg tablet has been studied in patients who had been diagnosed at least six months prior to beginning treatment and had an inadequate response to, or could not tolerate, one or more disease-modifying antirheumatic drugs (DMARDs). A 2016 clinical trial of about 3,300 RA patients found that baricitinib triggered an improvement in the signs and symptoms of RA within eight weeks in most study participants. This was measured by changes in an objective measure called the ACR20 response. Furthermore, this response was maintained over the 48-week study period.

    Improved action from these drugs

    Treatment with baricitinib has been found to reduce the number of joints damaged by RA and improve physical functioning. In clinical studies, baricitinib was shown to impede disease progression as seen by radiographic imaging. In all study periods up to one year, the drug has been observed to reduce the level of pain, morning stiffness, and fatigue in patients. Moreover, baricitinib has been found to decrease the need for painful and expensive injections because of its anti-inflammatory properties.

    In conclusion

    In this blog, you read about tab baricitinib 2mg uses & side effects. Baricitinib as a promising treatment option for those with refractory rheumatoid arthritis who have not responded to other treatments. It has been found to significantly reduce the signs and symptoms of RA and impede disease progression. What’s more, baricitinib has been observed to be safe with few severe side effects reported. All in all, baricitinib is an effective and safe treatment option for patients with refractory RA.